Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Humanetics entered the field of radiation modulators through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). AFRRI's mission is the discovery and early development of drugs that can protect warfighters from the harmful effects of radiation. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from the Department of Defense to Humanetics. In the ensuing years, the Company has progressed this program into clinical stage with a primary focus on improving the treatment outcomes for patients receiving radiation treatment of solid tumors. Humanetics has three open INDs for BIO 300. We have active clinical programs focused on medical countermeasures, solid tumor radiotherapy and in COVID-19. The Company has recently received a $20 million grant from the DoD for BIO 300.